Currently, the following drugs are first-line therapeutic options for LTP: C1INH concentrates (IV or SC), the monoclonal antibody lanadelumab that inhibits plasma kallikrein and is administered subcutaneously, and berotralstat, the only oral treatment option in HAE, which is also a kallikrein inhibitor [8]. The gene discussed is KLK4; the disease is hereditary angioedema.